MetaCap

Cel-Sci Corporation (CVM)

NYSE: CVMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

1.21-0.26 (-17.69%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CVM stock chart

Technical analysis

Key statistics

All statistics
Market cap
$21.28M
EPS (TTM)
-$1.69
52-week range
0.89 – 7.80
Day range
1.19 – 1.59
Volume / Avg
879.70K / 231.46K
Beta
—

52-week range

$0.89$7.80

CVM stock today

Cel-Sci (CVM) closed at $1.21 on Nov 20, down 17.69% (-$0.26), versus the S&P 500's 3.70% decline. Volume was 3.8x the average at 879.70K shares, a sign of unusually heavy trading. At this level, CVM sits near the bottom of its 52-week range of $0.89 to $7.80: 84.5% below the high, set on Nov 28, 2025 and 36.0% above the low.

CVM is down 77.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 80.7%. Cel-Sci has posted a net loss over the last twelve months (EPS of -$1.69), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Cel-Sci

Company profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Geert R. Kersten Esq.
Headquarters
Vienna, VA
IPO year
1997

Financial highlights

Full financials

Cel-Sci reported a net loss of $25.4 million, compared with a loss of $26.9 million a year earlier. Diluted earnings per share came in at -$6.27.

Cel-Sci annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-25.41M$-26.92M$-32.37M$-36.70M$-36.36M
EPS (diluted)$-6.27$-15.31$-0.73$-0.87$-0.90

Analyst forecast

Forecast

Consensus (2 analysts)

none

Avg. price target

$12.50+933.06%

  • Strong buy 1
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $10.00High $15.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Q3 2026)
Aug 14, 2026
EPS actual vs est.
$-0.47 vs —

CVM news

All CVM news

Cel-Sci peers

Health Care sector
CVM peer companies
CompanyPrice% ChgMarket capCompare
MGXMetagenomi Therapeutics Inc.0.565-7.95%$21.36Mvs CVM
EVAXEvaxion A/S ADR2.25+10.84%$20.75Mvs CVM
SAENGenenta Science S.p.A. ADR0.5074-9.39%$24.47Mvs CVM
PTHSPelthos Therapeutics Inc.6.38-8.73%$25.08Mvs CVM
INMBINmune Bio Inc.0.827-7.50%$25.60Mvs CVM
LONALeonaBio Inc.2.02-17.89%$26.41Mvs CVM
EXOZeXoZymes Inc.2.91-14.05%$27.42Mvs CVM
ESLAEstrella Immunopharma Inc.0.321-5.70%$14.11Mvs CVM

Indexes, lists and sector

Cel-Sci stock FAQ

What is Cel-Sci's stock price today?

CVM last traded at $1.21 as of Nov 20, 4:00 PM EST, down 17.69% on the day. Prices are delayed at least 15 minutes.

Does Cel-Sci pay a dividend?

No. Cel-Sci does not currently pay a regular cash dividend.

Who is Cel-Sci's CEO?

Mr. Geert R. Kersten Esq. is the chief executive officer of Cel-Sci Corporation.

Has CVM ever split its stock?

Yes. The most recent CVM stock split was a 1-for-30 split on May 20, 2025, one of 4 splits on record.

What is the CVM 52-week high?

The 52-week high for CVM is $7.80 and the 52-week low is $0.89. The stock is currently 84.5% below its high.

Compare CVM